Eutilex Co.,Ltd.
Develops T-cell and antibody immunotherapies for cancer and autoimmune diseases.
263050 | KO
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- South Korea
- Address:
- 서울특별시 금천구 가산디지털1로 58 408호 (가산동, 에이스한솔타워), 서울특별시
- Website:
- https://www.eutilex.com/en/
- Sector:
- Mining and quarrying
- Industry:
- Mining of non-ferrous metal ores
Description
Eutilex Co., Ltd. is a biotechnology company focused on the research and development of breakthrough immunotherapeutics for incurable diseases, particularly cancer and autoimmune disorders. The company's core activities are centered around three proprietary technology platforms: T-cell therapy, antibody therapy, and CAR-T cell therapy. Its pipeline includes adoptive T-cell therapies, such as 4-1BB cytotoxic T-lymphocytes (CTL), and immunomodulatory antibody therapeutics designed to act as immune checkpoint activators, stimulating T-cells to enhance anti-tumor immune responses. Eutilex's approach is based on selecting novel targets that effectively enhance or suppress human immune functions to treat diseases.
This is a Fraction of the Available Data.
You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for Eutilex Co.,Ltd. and 9,000+ other companies.
Stop analyzing yesterday's news. Start building a real-time advantage.
Request Enterprise API AccessFilings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| No filings match the current criteria. | ||||
Automate Your Workflow. Get a real-time feed of all Eutilex Co.,Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Eutilex Co.,Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
